Cardax Inc
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and w… Read more
Cardax Inc (CDXI) - Total Liabilities
Latest total liabilities as of March 2021: $12.73 Million USD
Based on the latest financial reports, Cardax Inc (CDXI) has total liabilities worth $12.73 Million USD as of March 2021.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cardax Inc - Total Liabilities Trend (2011–2020)
This chart illustrates how Cardax Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cardax Inc Competitors by Total Liabilities
The table below lists competitors of Cardax Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
British Smaller Companies Vct 2 Plc
LSE:BSC
|
UK | GBX515.00K |
|
Alternaturals Inc
PINK:ANAS
|
USA | $55.45K |
|
Caduceus Software Systems Corp
PINK:CSOC
|
USA | $8.98 Million |
|
Araneta Properties Inc
PSE:ARA
|
Philippines | ₱267.18 Million |
|
City and Land Developers Inc
PSE:LAND
|
Philippines | ₱361.11 Million |
|
Humble Energy Inc
PINK:HUML
|
USA | $987.67K |
|
O.A.T. Inc
PINK:OATN
|
USA | $996.18K |
|
China Intel Info Sys
PINK:IICN
|
USA | $3.73 Million |
Liability Composition Analysis (2011–2020)
This chart breaks down Cardax Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 9.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cardax Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cardax Inc (2011–2020)
The table below shows the annual total liabilities of Cardax Inc from 2011 to 2020.
| Year | Total Liabilities | Change |
|---|---|---|
| 2020-12-31 | $11.62 Million | +26.10% |
| 2019-12-31 | $9.22 Million | +53.78% |
| 2018-12-31 | $5.99 Million | +31.39% |
| 2017-12-31 | $4.56 Million | -1.59% |
| 2016-12-31 | $4.64 Million | +0.79% |
| 2015-12-31 | $4.60 Million | -3.39% |
| 2014-12-31 | $4.76 Million | -67.62% |
| 2013-12-31 | $14.70 Million | +68793.34% |
| 2012-12-31 | $21.34K | +644.73% |
| 2011-12-31 | $2.87K | -- |